Artefact Projects Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 26, 2025, 6:48 pm

Competitors of Artefact Projects Ltd

All Competitor Stocks of Artefact Projects Ltd

Quarterly Result

Last Updated: August 19, 2025, 11:25 pm

Below is a detailed analysis of the quarterly data for Artefact Projects Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 2.21 Cr.. The value appears to be declining and may need further review. It has decreased from 12.74 Cr. (Mar 2025) to 2.21 Cr., marking a decrease of 10.53 Cr..
• For Expenses, as of Jun 2025, the value is 1.64 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.44 Cr. (Mar 2025) to 1.64 Cr., marking a decrease of 8.80 Cr..
• For Operating Profit, as of Jun 2025, the value is 0.57 Cr.. The value appears to be declining and may need further review. It has decreased from 2.30 Cr. (Mar 2025) to 0.57 Cr., marking a decrease of 1.73 Cr..
• For OPM %, as of Jun 2025, the value is 25.79%. The value appears strong and on an upward trend. It has increased from 18.05% (Mar 2025) to 25.79%, marking an increase of 7.74%.
• For Other Income, as of Jun 2025, the value is 1.31 Cr.. The value appears strong and on an upward trend. It has increased from 1.30 Cr. (Mar 2025) to 1.31 Cr., marking an increase of 0.01 Cr..
• For Interest, as of Jun 2025, the value is 0.42 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.42 Cr..
• For Depreciation, as of Jun 2025, the value is 0.11 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.11 Cr..
• For Profit before tax, as of Jun 2025, the value is 1.35 Cr.. The value appears to be declining and may need further review. It has decreased from 3.07 Cr. (Mar 2025) to 1.35 Cr., marking a decrease of 1.72 Cr..
• For Tax %, as of Jun 2025, the value is 24.44%. The value appears to be increasing, which may not be favorable. It has increased from 2.93% (Mar 2025) to 24.44%, marking an increase of 21.51%.
• For Net Profit, as of Jun 2025, the value is 1.02 Cr.. The value appears to be declining and may need further review. It has decreased from 2.98 Cr. (Mar 2025) to 1.02 Cr., marking a decrease of 1.96 Cr..
• For EPS in Rs, as of Jun 2025, the value is 1.40. The value appears to be declining and may need further review. It has decreased from 4.10 (Mar 2025) to 1.40, marking a decrease of 2.70.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 3:55 am

Growth

Last Updated: September 5, 2025, 2:21 pm

Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Artefact Projects Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 16, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 15) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 16, the value is -9.26. This value is below the healthy minimum of 5. It has decreased from 3.40 (Mar 15) to -9.26, marking a decrease of 12.66.
• For Diluted EPS (Rs.), as of Mar 16, the value is -9.26. This value is below the healthy minimum of 5. It has decreased from 3.40 (Mar 15) to -9.26, marking a decrease of 12.66.
• For Cash EPS (Rs.), as of Mar 16, the value is -7.61. This value is below the healthy minimum of 3. It has decreased from 5.18 (Mar 15) to -7.61, marking a decrease of 12.79.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 63.88. It has decreased from 72.77 (Mar 15) to 63.88, marking a decrease of 8.89.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 63.88. It has decreased from 72.77 (Mar 15) to 63.88, marking a decrease of 8.89.
• For Revenue From Operations / Share (Rs.), as of Mar 16, the value is 53.95. It has decreased from 84.45 (Mar 15) to 53.95, marking a decrease of 30.50.
• For PBDIT / Share (Rs.), as of Mar 16, the value is 1.84. This value is below the healthy minimum of 2. It has decreased from 14.41 (Mar 15) to 1.84, marking a decrease of 12.57.
• For PBIT / Share (Rs.), as of Mar 16, the value is 0.18. This value is within the healthy range. It has decreased from 12.67 (Mar 15) to 0.18, marking a decrease of 12.49.
• For PBT / Share (Rs.), as of Mar 16, the value is -8.49. This value is below the healthy minimum of 0. It has decreased from 5.29 (Mar 15) to -8.49, marking a decrease of 13.78.
• For Net Profit / Share (Rs.), as of Mar 16, the value is -9.27. This value is below the healthy minimum of 2. It has decreased from 3.44 (Mar 15) to -9.27, marking a decrease of 12.71.
• For NP After MI And SOA / Share (Rs.), as of Mar 16, the value is -9.26. This value is below the healthy minimum of 2. It has decreased from 3.40 (Mar 15) to -9.26, marking a decrease of 12.66.
• For PBDIT Margin (%), as of Mar 16, the value is 3.41. This value is below the healthy minimum of 10. It has decreased from 17.06 (Mar 15) to 3.41, marking a decrease of 13.65.
• For PBIT Margin (%), as of Mar 16, the value is 0.33. This value is below the healthy minimum of 10. It has decreased from 14.99 (Mar 15) to 0.33, marking a decrease of 14.66.
• For PBT Margin (%), as of Mar 16, the value is -15.73. This value is below the healthy minimum of 10. It has decreased from 6.25 (Mar 15) to -15.73, marking a decrease of 21.98.
• For Net Profit Margin (%), as of Mar 16, the value is -17.19. This value is below the healthy minimum of 5. It has decreased from 4.07 (Mar 15) to -17.19, marking a decrease of 21.26.
• For NP After MI And SOA Margin (%), as of Mar 16, the value is -17.17. This value is below the healthy minimum of 8. It has decreased from 4.02 (Mar 15) to -17.17, marking a decrease of 21.19.
• For Return on Networth / Equity (%), as of Mar 16, the value is -14.50. This value is below the healthy minimum of 15. It has decreased from 4.67 (Mar 15) to -14.50, marking a decrease of 19.17.
• For Return on Capital Employeed (%), as of Mar 16, the value is 0.17. This value is below the healthy minimum of 10. It has decreased from 15.32 (Mar 15) to 0.17, marking a decrease of 15.15.
• For Return On Assets (%), as of Mar 16, the value is -5.48. This value is below the healthy minimum of 5. It has decreased from 2.02 (Mar 15) to -5.48, marking a decrease of 7.50.
• For Long Term Debt / Equity (X), as of Mar 16, the value is 0.52. This value is within the healthy range. It has increased from 0.08 (Mar 15) to 0.52, marking an increase of 0.44.
• For Total Debt / Equity (X), as of Mar 16, the value is 0.88. This value is within the healthy range. It has increased from 0.37 (Mar 15) to 0.88, marking an increase of 0.51.
• For Asset Turnover Ratio (%), as of Mar 16, the value is 0.19. It has decreased from 0.25 (Mar 15) to 0.19, marking a decrease of 0.06.
• For Current Ratio (X), as of Mar 16, the value is 1.46. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 15) to 1.46, marking an increase of 0.25.
• For Quick Ratio (X), as of Mar 16, the value is 1.34. This value is within the healthy range. It has increased from 1.09 (Mar 15) to 1.34, marking an increase of 0.25.
• For Dividend Payout Ratio (NP) (%), as of Mar 16, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 15) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 16, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 15) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 16, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 15) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 16, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 15) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 16, the value is 0.21. This value is below the healthy minimum of 3. It has decreased from 1.95 (Mar 15) to 0.21, marking a decrease of 1.74.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 16, the value is -0.06. This value is below the healthy minimum of 3. It has decreased from 1.47 (Mar 15) to -0.06, marking a decrease of 1.53.
• For Enterprise Value (Cr.), as of Mar 16, the value is 47.63. It has increased from 31.30 (Mar 15) to 47.63, marking an increase of 16.33.
• For EV / Net Operating Revenue (X), as of Mar 16, the value is 1.60. This value is within the healthy range. It has increased from 0.67 (Mar 15) to 1.60, marking an increase of 0.93.
• For EV / EBITDA (X), as of Mar 16, the value is 46.86. This value exceeds the healthy maximum of 15. It has increased from 3.93 (Mar 15) to 46.86, marking an increase of 42.93.
• For MarketCap / Net Operating Revenue (X), as of Mar 16, the value is 0.59. This value is below the healthy minimum of 1. It has increased from 0.43 (Mar 15) to 0.59, marking an increase of 0.16.
• For Retention Ratios (%), as of Mar 16, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 15) which recorded 0.00.
• For Price / BV (X), as of Mar 16, the value is 0.50. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 15) which recorded 0.50.
• For Price / Net Operating Revenue (X), as of Mar 16, the value is 0.59. This value is below the healthy minimum of 1. It has increased from 0.43 (Mar 15) to 0.59, marking an increase of 0.16.
• For EarningsYield, as of Mar 16, the value is -0.28. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 15) to -0.28, marking a decrease of 0.37.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness